Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 736362, 2 pages

Peroxisome Proliferator-Activated Receptor δ: A Target with a Broad Therapeutic Potential for Drug Discovery

Department of Biology, Metabolex Inc., Hayward, CA 94545, USA

Received 30 December 2008; Accepted 30 December 2008

Copyright © 2008 Francine M. Gregoire. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Loomba and R. Arora, “Fibrates: where are we now?,” Therapeutic Advances in Cardiovascular Disease, vol. 3, no. 1, pp. 91–96, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. F. Chiarelli and D. Di Marzio, “Peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives,” Vascular Health and Risk Management, vol. 4, no. 2, pp. 297–304, 2008. View at Google Scholar
  3. A. N. Billin, “PPAR-β/δ agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home,” Expert Opinion on Investigational Drugs, vol. 17, no. 10, pp. 1465–1471, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. K. S. Kilgore and A. N. Billin, “PPARβ/δ ligands as modulators of the inflammatory response,” Current Opinion in Investigational Drugs, vol. 9, no. 5, pp. 463–469, 2008. View at Google Scholar
  5. H. Lim, R. A. Gupta, W.-G. Ma et al., “Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ,” Genes & Development, vol. 13, no. 12, pp. 1561–1574, 1999. View at Google Scholar
  6. A. Tesse, R. Andriantsitohaina, and T. Ragot, “PPARδ activity in cardiovascular diseases: a potential pharmacological target,” PPAR Research, vol. 2009, Article ID 745821, 9 pages, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. P. A. Rittenhouse, “Dyslipidemia rescue,” BioCentury, The Bernstein Report on BioBusiness, pp. A12–A13, 2008. View at Google Scholar